Evidence map›Paper›PMID 29428715›Full record

ArticleThrombosis research2018

Routine clinical anti-platelet agents have limited efficacy in modulating hypershear-mediated platelet activation associated with mechanical circulatory support.

Lorenzo Valerio, Jawaad Sheriff, Phat L Tran, William Brengle, Alberto Redaelli, Gianfranco B Fiore, Federico Pappalardo, Danny Bluestein, Marvin J Slepian

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thrombosis research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Prothrombotic activity of cytokine-activated endothelial cells and shear-activated platelets in the setting of ventricular assist device support.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2019
    Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Lorenzo ValerioDepartment of Electronics, Information, and Bioengineering, Politecnico di Milano, Milan, Italy; Department of Cardiothoracic Anesthesia and Intensive Care, Istituto Scientifico San Raffaele, Milan, Italy.
Jawaad SheriffDepartment of Biomedical Engineering, Stony Brook University, Stony Brook, NY, USA.
Phat L TranDepartment of Biomedical Engineering, Sarver Heart Center, University of Arizona, Tucson, AZ, USA.
William BrengleDepartment of Biomedical Engineering, Sarver Heart Center, University of Arizona, Tucson, AZ, USA.
Alberto RedaelliDepartment of Electronics, Information, and Bioengineering, Politecnico di Milano, Milan, Italy.
Gianfranco B FioreDepartment of Electronics, Information, and Bioengineering, Politecnico di Milano, Milan, Italy.
Federico PappalardoDepartment of Cardiothoracic Anesthesia and Intensive Care, Istituto Scientifico San Raffaele, Milan, Italy.
Danny BluesteinDepartment of Biomedical Engineering, Stony Brook University, Stony Brook, NY, USA.
Marvin J SlepianDepartment of Biomedical Engineering, Stony Brook University, Stony Brook, NY, USA; Department of Biomedical Engineering, Sarver Heart Center, University of Arizona, Tucson, AZ, USA; Department of Medicine, Sarver Heart Center, University of Arizona, Tucson, AZ, USA. Electronic address: slepian@email.arizona.edu.
University of Arizona · USPolitecnico di Milano · ITStony Brook University · USVita-Salute San Raffaele University · IT

Funding

Optimizing Cardiovascular Device Thromboresistance for Eliminating AnticoagulantsU01EB012487 · NIBIB · STATE UNIVERSITY NEW YORK STONY BROOK · PI BLUESTEIN, DANNY · 2010 to 2014
$6.9M
Optimizing Cardiovascular Devices Thrombogenicity for Eliminating AnticoagulationR01EB008004 · NIBIB · STATE UNIVERSITY NEW YORK STONY BROOK · PI BLUESTEIN, DANNY · 2007 to 2009
$1.7M
NIBIB NIH HHS R01 EB008004NIBIB NIH HHS U01 EB012487
6 · The paper itself

Abstract

introductionContinuous flow ventricular assist devices (cfVADs) continue to be limited by thrombotic complications associated with disruptive flow patterns and supraphysiologic shear stresses. Patients are prescribed complex antiplatelet therapies, which do not fully prevent recurrent thromboembolic events. This is partially due to limited data on antiplatelet efficacy under cfVAD-associated shear conditions. MATERIALS AND

methodsWe investigated the efficacy of antiplatelet drugs directly acting on three pathways: (1) cyclooxygenase (aspirin), (2) phosphodiesterase (dipyridamole, pentoxifylline, cilostazol), and (3) glycoprotein IIb-IIIa (eptifibatide). Gel-filtered platelets treated with these drugs were exposed for 10min to either constant shear stresses (30dyne/cm RESULTS AND

conclusionsSignificant PAS reduction was observed for all drugs after exposure to 30dyne/cm

Indexed as

HumansPlatelet ActivationPlatelet Aggregation InhibitorsStress, MechanicalPlatelet Aggregation InhibitorsAspirinGlycoprotein IIb-IIIa inhibitorsMechanical circulatory supportPhosphodiesterase inhibitorsShear stressThrombosis

Identifiers

PMID29428715
PMCPMC5879002
OpenAlexW2772263333

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.